Optimal timing of re-excision in synovial sarcoma patients: Immediate intervention versus waiting for local recurrence.
local recurrence
re-excision
residual tumor
synovial sarcoma
unplanned excision
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
15
07
2023
received:
12
02
2023
accepted:
11
08
2023
medline:
15
11
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
To investigate the difference in efficacy of re-excision in synovial sarcoma patients with and without residual tumor following unplanned excision, and to compare the prognostic outcomes of immediate re-excision versus waiting for local recurrence. This study included synovial sarcoma patients who underwent re-excision at our center between 2009 and 2019, categorized into groups based on unplanned excision and local recurrence. Analyzed endpoints included overall survival (OS), local recurrence-free survival (LRFS), and distant relapse-free survival (DRFS). Prognostic factors associated with these three different survival outcomes were analyzed through the use of Kaplan-Meier curves and Cox regression approaches. In total, this study incorporated 109 synovial sarcoma patients, including 32 (29.4%) with no residual tumor tissue identified after re-excision, 31 (28.4%) with residual tumor tissue after re-excision, and 46 (42.2%) with local recurrence after initial excision. Patients were assessed over a median 52-month follow-up period. The respective 5-year OS, 5-year LRFS, and 5-year DRFS rates were 82.4%, 76.7%, and 74.2% for the nonresidual group, 80.6%, 80.4%, and 77.3% for the residual tumor tissue group, and 63.5%, 50.7%, and 46.3% for the local recurrence group. There was no significant difference in OS of nonresidual group and residual group patients after re-excision (p = 0.471). Concurrent or sequential treatment with chemotherapy and radiotherapy significantly reduced the risk of metastasis and mortality when compared with noncombined chemoradiotherapy, and was more effective in the local recurrence group (p < 0.05). Prompt and adequate re-excision is crucial for patients with synovial sarcoma who undergo initial inadequate tumor excision, and their prognosis is significantly better compared with patients who delay re-excision until local recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the difference in efficacy of re-excision in synovial sarcoma patients with and without residual tumor following unplanned excision, and to compare the prognostic outcomes of immediate re-excision versus waiting for local recurrence.
METHOD
METHODS
This study included synovial sarcoma patients who underwent re-excision at our center between 2009 and 2019, categorized into groups based on unplanned excision and local recurrence. Analyzed endpoints included overall survival (OS), local recurrence-free survival (LRFS), and distant relapse-free survival (DRFS). Prognostic factors associated with these three different survival outcomes were analyzed through the use of Kaplan-Meier curves and Cox regression approaches.
RESULT
RESULTS
In total, this study incorporated 109 synovial sarcoma patients, including 32 (29.4%) with no residual tumor tissue identified after re-excision, 31 (28.4%) with residual tumor tissue after re-excision, and 46 (42.2%) with local recurrence after initial excision. Patients were assessed over a median 52-month follow-up period. The respective 5-year OS, 5-year LRFS, and 5-year DRFS rates were 82.4%, 76.7%, and 74.2% for the nonresidual group, 80.6%, 80.4%, and 77.3% for the residual tumor tissue group, and 63.5%, 50.7%, and 46.3% for the local recurrence group. There was no significant difference in OS of nonresidual group and residual group patients after re-excision (p = 0.471). Concurrent or sequential treatment with chemotherapy and radiotherapy significantly reduced the risk of metastasis and mortality when compared with noncombined chemoradiotherapy, and was more effective in the local recurrence group (p < 0.05).
CONCLUSION
CONCLUSIONS
Prompt and adequate re-excision is crucial for patients with synovial sarcoma who undergo initial inadequate tumor excision, and their prognosis is significantly better compared with patients who delay re-excision until local recurrence.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1394-1406Subventions
Organisme : Beijing Medical and Health Foundation
Informations de copyright
© 2023 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.
Références
Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma. An analysis of 134 tumors. Cancer. 1965;18(5):613-627.
Riedel R, Jones R, Italiano A, et al. Systemic anti-cancer therapy in synovial sarcoma: a systematic review. Cancers. 2018;10(11):417.
Zhang H, Huang W, Feng Q, et al. Clinical significance and risk factors of local recurrence in synovial sarcoma: a retrospective analysis of 171 cases. Front Surg. 2022;8:736146.
Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg. 1994;219(2):165-173.
Fletcher CDM, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press; 2002.
Weiss SW, Goldblum JR. Malignant soft tissue tumors of uncertain type. In: Weiss SW, Goldblum JR, eds. Enzinger and Weiss's Soft Tissue Tumors. 4th ed. Mosby; 2001:1483-1571.
Chandrasekar CR, Wafa H, Grimer RJ, Carter SR, Tillman RM, Abudu A. The effect of an unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg Br. 2008;90(2):203-208.
Trovik CS, Scandinavian Sarcoma Group P. Local recurrence of soft tissue sarcoma. A scandinavian sarcoma group project. Acta Orthop Scand Suppl. 2001;72(300):1-31.
Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of a soft-tissue sarcoma of an extremity. J Bone Joint Surg Am. 1996;78(5):650-655.
Tedesco NS, Henshaw RM. Unplanned resection of sarcoma. J Am Acad Orthop Surg. 2016;24(3):150-159.
Traub F, Griffin AM, Wunder JS, Ferguson PC. Influence of unplanned excisions on the outcomes of patients with stage III extremity soft-tissue sarcoma. Cancer. 2018;124(19):3868-3875.
Temple HT, Worman DS, Mnaymneh WA. Unplanned surgical excision of tumors of the foot and ankle. Cancer Control. 2001;8(3):262-268.
Choi ES, Han I, Cho HS, Kang HG, Kim JH, Kim HS. Distinct clinical characteristics of unplanned excision in synovial sarcoma. Clin Orthop Surg. 2015;7(2):254-260.
Decanter G, Stoeckle E, Honore C, et al. Watch and wait approach for re-excision after unplanned yet macroscopically complete excision of extremity and superficial truncal soft tissue sarcoma is safe and does not affect metastatic risk or amputation rate. Ann Surg Oncol. 2019;26(11):3526-3534.
Rehders A, Stoecklein NH, Poremba C, Alexander A, Knoefel WT, Peiper M. Reexcision of soft tissue sarcoma: sufficient local control but increased rate of metastasis. World J Surg. 2009;33(12):2599-2605.
Zagars GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003;97(10):2544-2553.
Shemesh SS, Garbrecht EL, Rutenberg TF, Conway SA, Rosenberg AE, Pretell-Mazzini J. Unplanned excision of soft tissue sarcoma: does it impact the accuracy of intra-operative pathologic assessment at time of re-excision? Int Orthop. 2021;45(11):2983-2991.
Qureshi YA, Huddy JR, Miller JD, Strauss DC, Thomas JM, Hayes AJ. Unplanned excision of soft tissue sarcoma results in increased rates of local recurrence despite full further oncological treatment. Ann Surg Oncol. 2012;19(3):871-877.
Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18(22):3794-3803.
Potter BK, Adams SC, Pitcher DJ Jr, Temple TH. Local recurrence of disease after unplanned excisions of high-grade soft tissue sarcomas. Clin Orthop Relat Res. 2008;466(12):3093-3100.
Lin PP, Guzel VB, Pisters PWT, et al. Surgical management of soft tissue sarcomas of the hand and foot. Cancer. 2002;95(4):852-861.
Fiore M, Casali PG, Miceli R, et al. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13(1):110-117.
Charoenlap C, Imanishi J, Tanaka T, et al. Outcomes of unplanned sarcoma excision: impact of residual disease. Cancer Med. 2016;5(6):980-988.
Koulaxouzidis G, Schwarzkopf E, Bannasch H, Stark GB. Is revisional surgery mandatory when an unexpected sarcoma diagnosis is made following primary surgery? World J Surg Oncol. 2015;Oct 24 13:306.
Sacchetti F, Alsina AC, Morganti R, et al. Re-excision after unplanned excision of soft tissue sarcoma: a systematic review and metanalysis. the rationale of systematic re-excision. J Orthop. 2021;25:244-251.
Bonvalot S, Levy A, Terrier P, et al. Primary extremity soft tissue sarcomas: does local control impact survival? Ann Surg Oncol. 2017;24(1):194-201.
Scheer M, Dantonello T, Hallmen E, et al. Synovial sarcoma recurrence in children and young adults. Ann Surg Oncol. 2016;23(suppl 5):618-626.
Davies AM, Mehr A, Parsonage S, Evans N, Grimer RJ, Pynsent PB. MR imaging in the assessment of residual tumour following inadequate primary excision of soft tissue sarcomas. Eur Radiol. 2004;14(3):506-513.
Kepka L, Suit HD, Goldberg SI, et al. Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol. 2005;92(1):39-45.
Morii T, Yabe H, Morioka H, Anazawa U, Suzuki Y, Toyama Y. Clinical significance of additional wide resection for unplanned resection of high grade soft tissue sarcoma. Open Orthop J. 2008;2:126-129.
Scoccianti G, Innocenti M, Frenos F, et al. Re-excision after unplanned excision of soft tissue sarcomas: long-term results. Surg Oncol. 2020;34:212-217.
Han I, Kang HG, Kang SC, Choi JR, Kim HS. Does delayed reexcision affect outcome after unplanned excision for soft tissue sarcoma? Clin Orthop Relat Res. 2011;469(3):877-883.
Davis AM, Kandel RA, Wunder JS, et al. The impact of residual disease on local recurrence in patients treated by initial unplanned resection for soft tissue sarcoma of the extremity. J Surg Oncol. 1997;66(2):81-87.
Chotel F, Unnithan A, Chandrasekar CR, Parot R, Jeys L, Grimer RJ. Variability in the presentation of synovial sarcoma in children: a plea for greater awareness. J Bone Joint Surg Br. 2008;90(8):1090-1096.
Lewis JJ, Leung D, Espat J, Woodruff JM, Brennan MF. Effect of reresection in extremity soft tissue sarcoma. Ann Surg. 2000;231(5):655-663.
Jones DA, Shideman C, Yuan J, et al. Management of unplanned excision for soft-tissue sarcoma with preoperative radiotherapy followed by definitive resection. Am J Clin Oncol. 2016;39(6):586-592.
Saeed H, King DM, Johnstone CA, et al. Preoperative radiation therapy followed by reexcision may improve local control and progression-free survival in unplanned excisions of soft tissue sarcomas of the extremity and chest-wall. Int J Surg Oncol. 2016;2016:1-8.
Manoso MW, Pratt J, Healey JH, Boland PJ, Athanasian EA. Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res. 2006;450:89-94.
Mullen JR, Zagars GK. Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol. 1994;33:23-30.
Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627-634.
Vining CC, Sinnamon AJ, Ecker BL, et al. Adjuvant chemotherapy in resectable synovial sarcoma. J Surg Oncol. 2017;116(4):550-558.
Chen Y, Yang Y, Wang C, Shi Y. Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients. J Surg Oncol. 2012;106(2):162-168.